

Constantin Volovat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7938492/publications.pdf>

Version: 2024-02-01

36
papers

12,203
citations

471477

17
h-index

477281

29
g-index

38
all docs

38
docs citations

38
times ranked

17622
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015, 373, 1803-1813.	27.0	4,889
2	Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 352-360.	27.0	1,588
3	Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease. <i>New England Journal of Medicine</i> , 2012, 367, 2407-2418.	27.0	1,267
4	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 122-131.	27.0	1,033
5	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 499-508.	10.7	753
6	Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 490-499.	10.7	740
7	Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 601-609.	27.0	489
8	Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 59-68.	10.7	446
9	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 763-774.	10.7	431
10	KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. <i>Journal of Clinical Oncology</i> , 2008, 26, 4000-4000.	1.6	152
11	Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 328-337.	10.7	124
12	Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 617-625.	2.4	74
13	<i>KRAS</i>, <i>NRAS</i> and <i>BRAF</i> mutations in Greek and Romanian patients with colorectal cancer: a cohort study. <i>BMJ Open</i> , 2014, 4, e004652.	1.9	29
14	Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1069-1077.	3.8	27
15	Efficacy and Safety of Balugrastim Compared With Pegfilgrastim in Patients With Breast Cancer Receiving Chemotherapy. <i>Clinical Breast Cancer</i> , 2014, 14, 101-108.	2.4	21
16	Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Squamous Non-€Small-Cell Lung Cancer: Results From the Randomized Controlled MONET1 Study. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1154-1161.	1.1	19
17	Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy. <i>SpringerPlus</i> , 2015, 4, 316.	1.2	17
18	A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer. <i>Oncotarget</i> , 2020, 11, 3105-3117.	1.8	15

#	ARTICLE	IF	CITATIONS
19	Nephrotoxicity/renal failure after therapy with ⁹⁰ Yttrium- and ¹⁷⁷ Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review. Nuclear Medicine Communications, 2020, 41, 601-617.	1.1	14
20	Theoretical model for the diclofenac release from PEGylated chitosan hydrogels. Drug Delivery, 2021, 28, 261-271.	5.7	10
21	Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients. Supportive Care in Cancer, 2016, 24, 4913-4920.	2.2	8
22	The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis. Journal of Chemotherapy, 2016, 28, 235-241.	1.5	6
23	Radiomics in Triple Negative Breast Cancer: New Horizons in an Aggressive Subtype of the Disease. Journal of Clinical Medicine, 2022, 11, 616.	2.4	6
24	Update on the Use of Nanocarriers and Drug Delivery Systems and Future Directions in Cervical Cancer. Journal of Immunology Research, 2022, 2022, 1-11.	2.2	6
25	"Liquid Biopsy" - Is it a Feasible Option in Colorectal Cancer?. Chirurgia (Romania), 2019, 114, 162.	0.5	5
26	A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Afibercept in Cancer Patients Treated With Docetaxel. Journal of Cardiovascular Pharmacology, 2013, 61, 495-504.	1.9	4
27	Pharmacokinetics and in vivo stability of intraperitoneally administered therapeutic antibody catumaxomab. Journal of Clinical Oncology, 2008, 26, 14006-14006.	1.6	4
28	Predictive Value of HPV, p53, and p16 in the Post-Treatment Evolution of Malignant Tumors of the Oropharynx and Retromolar Trigone "Oropharynx Junction. Medicina (Lithuania), 2020, 56, 542.	2.0	1
29	Abstract 4606: Randomized phase 2 study of efatutazone in combination with carboplatin and paclitaxel as first-line therapy for metastatic non-small cell lung cancer (NSCLC). , 2012, , .		1
30	5163 POSTER Quality of Life of Women With Breast Cancer Treated in Adjuvant Setting With Tamoxifen or Aromatase Inhibitors. European Journal of Cancer, 2011, 47, S379.	2.8	0
31	Efficacy of Lipegfilgrastim (Lipeg) and Pegfilgrastim (Peg) in Breast Cancer Patients Receiving Chemotherapy (Ctx) Stratified By Status, Age, and Disease Stageby Status, Age, and Disease Stage. Annals of Oncology, 2014, 25, iv522.	1.2	0
32	Efficacy and safety of balugrastim in chemotherapy-induced neutropenia: Integrated analysis of two randomized phase III studies.. Journal of Clinical Oncology, 2013, 31, e17572-e17572.	1.6	0
33	Pancreatic neuroendocrine tumour with a silent long evolution: case report. Endocrine Abstracts, 0, , .	0.0	0
34	Concomitance of pancreatic and neuroendocrine breast tumour - simple coincidence or not?. Endocrine Abstracts, 0, , .	0.0	0
35	Primitive Gastric Lymphoma - a Series of 3 Cases. Revista De Chimie (discontinued), 2020, 71, 416-419.	0.4	0
36	Contribution of Pathology in Surgical Oncology in Malignant Tumors of the Salivary Glands. Revista De Chimie (discontinued), 2020, 71, 420-425.	0.4	0